The CLARIFY Decision Support Platform (DSP) is a responsive web application designed to support decision-making in cancer care through real-time data integration and predictive analytics. Built on Big Data Europe, the platform integrates a variety of data, including scientific publications, clinical anonymized data from EHR, genomic data, wearable monitoring data, and quality of life questionnaires. This data is presented in an intuitive and user-friendly dashboard. The goal of the CLARIFY project (Cancer Long Survivor Artificial Intelligence Follow-Up) is to use an Artificial Intelligence (AI)-driven decision support platform to stratify cancer patients by risk factors, predict survival rates and improve the personalization of post-treatment care. The target audience includes cancer patients, caregivers, healthcare professionals, and public health policymakers. The project addresses several areas of digital health, particularly precision medicine, data integration, and big data predictive analytics.
From Big Data to Big Decisions: How AI Stratifies Cancer Cases by Risk Factors From Big Data to Big Decisions: How AI Stratifies Cancer Cases by Risk Factors From Big Data to Big Decisions: How AI Stratifies Cancer Cases by Risk Factors From Big Data to Big Decisions: How AI Stratifies Cancer Cases by Risk Factors

Home / Publications / Publication

Home / Publications / Publication

CLARIFY Oncologia
Image reproduced from the CLARIFY website.

Publication type: Article Summary
Original title: An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
Article publication date: August 2022
Source: Cancers (Basel)
Authors: María Torrente, Pedro A. Sousa, Roberto Hernández, Mariola Blanco, Virginia Calvo, Ana Collazo, Gracinda R. Guerreiro, Beatriz Núñez, Joao Pimentao, Juan Cristóbal Sánchez, Manuel Campos, Luca Costabello, Vit Novacek, Ernestina Menasalvas, María Esther Vidal & Mariano Provencio

What is the goal, target audience, and areas of digital health it addresses?
     The goal of the CLARIFY project (Cancer Long Survivor Artificial Intelligence Follow-Up) is to use an Artificial Intelligence (AI)-driven decision support platform to stratify cancer patients by risk factors, predict survival rates and improve the personalization of post-treatment care. The target audience includes cancer patients, caregivers, healthcare professionals, and public health policymakers. The project addresses several areas of digital health, particularly precision medicine, data integration, and big data predictive analytics.

What is the context?
     The rising complexity of cancer care, along with the increasing volume of healthcare data from electronic health records (EHR), wearable devices, and genomic testing, creates both challenges and opportunities for effective patient management. As cancer remains a leading cause of death worldwide, the integration of AI in healthcare is essential for enhancing patient outcomes.

     AI has significantly advanced the resolution of biomedical challenges by enabling the analysis of large-scale, multidimensional data. While AI advancements in early detection are notable, implementing personalized care remains challenging due to lack of standardization and insufficient clinical validation. Despite these barriers, the potential for AI to revolutionize oncology care by improving survival rates and the overall efficiency of clinical workflows is increasingly recognized.

What are the current approaches?
     Current approaches in oncology typically involve standardized treatment protocols that adopt a reactive “one-size-fits-all” strategy, often neglecting individual patient characteristics and genetic profiles. These conventional methods rely primarily on the clinical experience of healthcare professionals, which can result in variability in healthcare for each patient.

What does CLARIFY platform consist of? How is the impact of CLARIFY project assessed?
     The CLARIFY Decision Support Platform (DSP) is a responsive web application designed to support decision-making in cancer care through real-time data integration and predictive analytics. Built on Big Data Europe, the platform integrates a variety of data, including scientific publications, clinical anonymized data from EHR, genomic data, wearable monitoring data, and quality of life questionnaires. This data is presented in an intuitive and user-friendly dashboard.

     The CLARIFY DSP uses statistical tools like Kaplan-Meier estimates to calculate the survival probabilities over time and Cox Regression models to analyze how factors such as age affect survival time, facilitating detailed individual and population-level analyses. Additionally, it employs machine learning algorithms, including neural networks, to predict patient outcomes as well as statistical relational learning to discover data patterns. Explainable AI is also integrated to enhance comprehension of AI decision-making, enabling clinicians to make evidence-based treatment decisions and personalized follow-up care while improving their understanding of disease progression and risk factors.

     To test the CLARIFY project, a prognostic model was developed using data from 1,348 early-stage non-small cell lung cancer (NSCLC) patients. This model used AI for tumor recurrence prediction, relying solely on clinical data to analyze similar patient profiles and generate individual recurrence probabilities along with AI-generated explanations for each prediction. The model focused on identifying risk factors as gender, age, smoking status and treatment. The CLARIFY project’s impact was also evaluated in patients with breast cancer and non-Hodgkin’s lymphoma across multiple institutions in Spain, using the various data that the platform was designed to integrate.

What are the main results? What is the impact of these results? What is the future of this technology?
     The prognostic model for patients with NSCLC identified high-risk characteristics: men over 70 years old, former smokers, who underwent surgery, and low-risk factors: women between 20 and 50 years old, non-smokers, who underwent surgery and adjuvant chemotherapy. Overall, the CLARIFY project demonstrated effectiveness in stratifying patients by risk and identifying significant prognostic factors. The predictive models demonstrated the platform’s ability to forecast outcomes across various cancers, enabling oncologists to compare results between different pathologies and patient groups from multiple hospitals.

     The CLARIFY project’s findings have deepened the understanding of cancer treatment dynamics, which can have a positive impact on public health strategies to optimize care delivery. Future enhancements will incorporate sequencing data and rare mutations to enrich predictive capabilities and advance precision medicine. In the future, healthcare professionals will explain AI’s role in decision-making, empowering patients to take charge of their health through effective self-monitoring.

Do you have an innovative idea in healthcare field?

Share it with us and see it come to life.
We will help bring your projects to life!

Newsletter

Receive the latest updates from the InovarSaúde portal.

República Portuguesa logo
logotipo SNS
SPMS logotipo

Follow Us

YouTube
LinkedIn

Co-funded by

PRR Logotipo
república Portuguesa logo
União Europeia Logo

Newsletter

Receive the latest updates from the InovarSaúde portal.

República Portuguesa logo
SNS Logo
SPMS Logo

Follow Us

Co-funded by

PRR Logotipo
República Portuguesa logo
União Europeia Logo

Home / Publications / Publication

CLARIFY Oncologia
Image reproduced from the CLARIFY website.

Publication type: Article Summary
Original title: An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
Article publication date: August 2022
Source: Cancers (Basel)
Authors: María Torrente, Pedro A. Sousa, Roberto Hernández, Mariola Blanco, Virginia Calvo, Ana Collazo, Gracinda R. Guerreiro, Beatriz Núñez, Joao Pimentao, Juan Cristóbal Sánchez, Manuel Campos, Luca Costabello, Vit Novacek, Ernestina Menasalvas, María Esther Vidal & Mariano Provencio

What is the goal, target audience, and areas of digital health it addresses?
     The goal of the CLARIFY project (Cancer Long Survivor Artificial Intelligence Follow-Up) is to use an Artificial Intelligence (AI)-driven decision support platform to stratify cancer patients by risk factors, predict survival rates and improve the personalization of post-treatment care. The target audience includes cancer patients, caregivers, healthcare professionals, and public health policymakers. The project addresses several areas of digital health, particularly precision medicine, data integration, and big data predictive analytics.

What is the context?
     The rising complexity of cancer care, along with the increasing volume of healthcare data from electronic health records (EHR), wearable devices, and genomic testing, creates both challenges and opportunities for effective patient management. As cancer remains a leading cause of death worldwide, the integration of AI in healthcare is essential for enhancing patient outcomes.

     AI has significantly advanced the resolution of biomedical challenges by enabling the analysis of large-scale, multidimensional data. While AI advancements in early detection are notable, implementing personalized care remains challenging due to lack of standardization and insufficient clinical validation. Despite these barriers, the potential for AI to revolutionize oncology care by improving survival rates and the overall efficiency of clinical workflows is increasingly recognized.

What are the current approaches?
     Current approaches in oncology typically involve standardized treatment protocols that adopt a reactive “one-size-fits-all” strategy, often neglecting individual patient characteristics and genetic profiles. These conventional methods rely primarily on the clinical experience of healthcare professionals, which can result in variability in healthcare for each patient.

What does CLARIFY platform consist of? How is the impact of CLARIFY project assessed?
     The CLARIFY Decision Support Platform (DSP) is a responsive web application designed to support decision-making in cancer care through real-time data integration and predictive analytics. Built on Big Data Europe, the platform integrates a variety of data, including scientific publications, clinical anonymized data from EHR, genomic data, wearable monitoring data, and quality of life questionnaires. This data is presented in an intuitive and user-friendly dashboard.

     The CLARIFY DSP uses statistical tools like Kaplan-Meier estimates to calculate the survival probabilities over time and Cox Regression models to analyze how factors such as age affect survival time, facilitating detailed individual and population-level analyses. Additionally, it employs machine learning algorithms, including neural networks, to predict patient outcomes as well as statistical relational learning to discover data patterns. Explainable AI is also integrated to enhance comprehension of AI decision-making, enabling clinicians to make evidence-based treatment decisions and personalized follow-up care while improving their understanding of disease progression and risk factors.

     To test the CLARIFY project, a prognostic model was developed using data from 1,348 early-stage non-small cell lung cancer (NSCLC) patients. This model used AI for tumor recurrence prediction, relying solely on clinical data to analyze similar patient profiles and generate individual recurrence probabilities along with AI-generated explanations for each prediction. The model focused on identifying risk factors as gender, age, smoking status and treatment. The CLARIFY project’s impact was also evaluated in patients with breast cancer and non-Hodgkin’s lymphoma across multiple institutions in Spain, using the various data that the platform was designed to integrate.

What are the main results? What is the impact of these results? What is the future of this technology?
     The prognostic model for patients with NSCLC identified high-risk characteristics: men over 70 years old, former smokers, who underwent surgery, and low-risk factors: women between 20 and 50 years old, non-smokers, who underwent surgery and adjuvant chemotherapy. Overall, the CLARIFY project demonstrated effectiveness in stratifying patients by risk and identifying significant prognostic factors. The predictive models demonstrated the platform’s ability to forecast outcomes across various cancers, enabling oncologists to compare results between different pathologies and patient groups from multiple hospitals.

     The CLARIFY project’s findings have deepened the understanding of cancer treatment dynamics, which can have a positive impact on public health strategies to optimize care delivery. Future enhancements will incorporate sequencing data and rare mutations to enrich predictive capabilities and advance precision medicine. In the future, healthcare professionals will explain AI’s role in decision-making, empowering patients to take charge of their health through effective self-monitoring.

Perturbação do sono

A Digital Intervention for Insomnia in Oncology

Insomnia is a sleep disorder characterised by persistent difficulties in initiating sleep, maintaining sleep during the night, or achieving restful sleep. These difficulties arise even in the presence of adequate sleeping conditions and are often…

Read more
Sistema de telemonitorização remota

Digital Technology Revolutionising Post-cardiac Surgery

According to the World Health Organisation, cardiovascular disease remains the leading cause of death worldwide, responsible for around 17.9 million deaths a year. Its high prevalence is associated with unhealthy lifestyles characterised by poor diet,…

Read more
Sistema robótico autónomo INSIDE

Autonomous Robotics System for Autism Therapy

Autism spectrum disorder is a neurodevelopmental condition with significant clinical, social and economic repercussions throughout life. According to the World Health Organization, it is estimated to affect approximately 1 in 160 children worldwide. Its origin…

Read more
Enfermeira com um telefone

Mobile Application to Improve Workflows in Nursing Homes

Portugal has one of the highest aging populations in the world, placing increasing pressure on elderly care services, especially in nursing homes. Healthcare professionals in these facilities are often overwhelmed due to the increasing number…

Read more
troca de informações de saúde e interoperabilidade

New Era of Interoperability in Healthcare Systems

The growing use of electronic health records, digital diagnostic systems and remote monitoring technologies has led to a significant increase in the volume and complexity of health data. This increase intensifies the need for continuous,…

Read more
robótica colaborativa

Collaborative Robotics Improves Working Conditions

Workers face growing challenges in the industrial environment. Among the most critical are fatigue and inappropriate postures, often associated with repetitive tasks and working conditions that lack ergonomic suitability. These factors represent significant risks for…

Read more
Benefícios da Eletrônica Médica

Detection of Anxiety and Panic Attacks in Real Time

The growing number of people with anxiety disorders, along with increased awareness of mental health, drives the need for new technological tools that provide remote and continuous monitoring of anxiety and panic disorders. Thus, the…

Read more
tele-ecografia

A Novel Approach for Robotic-assisted Tele-echography

Currently, robotic systems for ultrasound diagnostic procedures fall into two main categories: portable robots that require manual positioning and fully autonomous robotic systems that independently control the ultrasound probe’s orientation and positioning. Portable robots rely…

Read more
Personalização e tecnologia na gestão da Diabetes

Personalization and Technology in Diabetes Management

IPDM has significant potential to improve diabetes management and drive health system reforms to become high-performing, effective, equitable, accessible, and sustainable. Evidence and good practices inspire health system transformation. Adopting person-centred approaches like co-creation and…

Read more
TEF-HEALTH Logo

SPMS Integrates the TEF-Health Initiative

SPMS participates in the TEF-Health initiative as a partner in a consortium composed of 51 entities from 9 European Union countries. This action is co-financed by the European Commission and has a duration of five…

Read more
Global Digital Health Partnership Logo

SPMS Represents Portugal as Vice-president of GDHP

The GDHP is an intergovernmental organization in the digital health sector that facilitates cooperation and collaboration between government representatives and the World Health Organization (WHO). Its purpose is to foster policymaking that promote the digitalization…

Read more
Portugal INCoDe.2030

Digital Transformation of Health at INCoDe.2030 in Tomar

The “National Digital Skills Initiative e.2030, Portugal” (INCoDe.2030) is an initiative that aims to improve the Portuguese population’s level of digital skills, placing Portugal at the level of the most advanced European countries in this…

Read more
HealthData@PT Logo

HealthData@PT: New SPMS Initiative for Health Data

Action HealthData@PT is launched in the context of the implementation of the European Health Data Space, and is an initiative approved by the European Commission under the EU4Health 2021-2027 programme. This initiative contributes to the…

Read more

Do you have an innovative idea in healthcare field?

Share it with us and see it come to life.
We will help bring your projects to life!

Newsletter

Receive the latest updates from the Inovarsaúde portal.

República Portuguesa logo
SNS Logo
SPMS Logo

Follow Us

YouTube
LinkedIn

Co-funded by

PRR Logotipo
República Portuguesa logo
União Europeia Logo
Scroll to Top